Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · March 24, 2024

Neoadjuvant–Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for the Treatment of Resectable NSCLC

JAMA Network Open

 

Additional Info

JAMA Network Open
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis
JAMA Netw Open 2024 Mar 04;7(3)e241285, Y Zhou, A Li, H Yu, Y Wang, X Zhang, H Qiu, W Du, L Luo, S Fu, L Zhang, S Hong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading